A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE patients who initiate anifrolumab treatment. ASTER will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.

Inclusion Criteria: * Fulfilled the 2019 EULAR (European League Against Rheumatism)/ACR (American College of Rheumatology) criteria for SLE at the time of study entry. * Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label. * The Physician's decision to prescribe anifrolumab must occur prior to any study-related discussion. * In countries where prescription reimbursements are authorised on a case-by-case basis, authorisation (ie, patient access to treatment) will be required for study entry. Exclusion Criteria: * Currently participating in an anifrolumab early access/compassionate use program or an interventional clinical trial with an investigational product. * Any previous exposure to anifrolumab (including as part of a clinical trial or early access programme). * Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \[MMF\]/cyclophosphamide \[CYC\] + high dose steroids), isolated Class V lupus nephritis (in absence of other SLE manifestations, ie. skin/joint involvement), or active severe or unstable neuropsychiatric lupus. * Any other condition which the investigator deems to limit a patient's ability to understand the informed consent.